HCC
MDCO

Hirtle Callaghan & Co’s Medicines Co MDCO Stock Holding History

Hirtle Callaghan & Co’s Portfolio MDCO Stock Details MDCO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-170
Closed -$5K – 410
2014
Q4 		$5K Hold
170
– – ﹤0.01% 466
2014
Q3 		$4K Hold
170
– – ﹤0.01% 517
2014
Q2 		$5K Hold
170
– – ﹤0.01% 539
2014
Q1 		$5K Hold
170
– – ﹤0.01% 526
2013
Q4 		$7K Hold
170
– – ﹤0.01% 490
2013
Q3 		$6K Buy
+170
New +$5.42K ﹤0.01% 510

Other funds holding MDCO

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Hirtle Callaghan & Co's MDCO Position: Q1 2015 in Review

Hirtle Callaghan & Co sold out of Medicines Co (MDCO) in Q1 2015, closing a stake of 170 shares — an estimated $5K sold.

Hirtle Callaghan & Co first reported a position in MDCO in Q3 2013 and held it in 6 quarters. The position peaked at $7K in Q4 2013. 184 funds tracked by Wall St. Rank hold MDCO as of Q1 2015.

  • Hirtle Callaghan & Co reported no remaining Medicines Co position as of Q1 2015 after selling out during the quarter.
  • Hirtle Callaghan & Co sold 170 Medicines Co shares in Q1 2015, an estimated $5K.
  • Hirtle Callaghan & Co first reported a position in Medicines Co in Q3 2013 and held it in 6 quarters.
  • Hirtle Callaghan & Co's Medicines Co position peaked at $7K in Q4 2013.
  • 184 funds tracked by Wall St. Rank held Medicines Co as of Q1 2015.

Based on Hirtle Callaghan & Co's 13F filing for Q1 2015, filed 15 May 2015.